Non-enzymatic glycation of low density lipoprotein (LDL) has been suggested to be responsible for the increase in susceptibility to atherogenesis of diabetic individuals. Although the association of lipid glycation with this process has been investigated, the effect of specific lipid glycation products on LDL metabolism has not been addressed. This study reports that glucosylated phosphatidylethanolamine (Glc-PtdEtn), the major LDL lipid glycation product, promotes LDL uptake and cholesteryl ester (CE) and triacylglycerol (TG) accumulation by THP-1 macrophages. Incubation of THP-1 macrophages at a concentration of 100 g/ml protein LDL specifically enriched (10 nmol/mg LDL protein) with synthetically prepared Glc-PtdEtn resulted in a significant increase in CE and TG accumulation when compared with LDL enriched in non-glucosylated PtdEtn. After a 24-h incubation with LDL containing Glc-PtdEtn, the macrophages contained 2-fold higher CE (10.11 ؎ 1.54 g/mg cell protein) and TG (285.32 ؎ 4.38 g/mg cell protein) compared with LDL specifically enriched in non-glucosylated PtdEtn (CE, 3.97 ؎ 0.95, p < 0.01 and TG, 185.57 ؎ 3.58 g/mg cell protein, p < 0.01).The corresponding values obtained with LDL containing glycated protein and lipid were similar to those of LDL containing Glc-PtdEtn (CE, 11.9 ؎ 1.35 and TG, 280.78 ؎ 3.98 g/mg cell protein). The accumulation of both neutral lipids was further significantly increased by incubating the macrophages with Glc-PtdEtn LDL exposed to copper oxidation. By utilizing the fluorescent probe, 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate (DiI), a 1.6-fold increase was seen in Glc-PtdEtn ؉ LDL uptake when compared with control LDL. Competition studies revealed that acetylated LDL is not a good competitor for DiI Glc-PtdEtn LDL (5-6% inhibition), whereas glycated LDL gave an 80% inhibition, and LDL ؉ Glc-PtdEtn gave 93% inhibition of uptake by macrophages. These results indicate that glucosylation of PtdEtn in LDL accounts for the entire effect of LDL glycation on macrophage uptake and CE and TG accumulation and, therefore, the increased atherogenic potential of LDL in hyperglycemia.
LDL1 glycation has been proposed to play central role in the atherosclerosis of diabetic hyperglycemia (1). The effect of protein glycation in LDL modification and its oxidation has been extensively investigated. Several groups of investigators have shown that glycated LDL is capable of inducing foam cell formation in a variety of cell culture systems (2-5). Furthermore, LDL from diabetic patients has been shown to increase accumulation of CE in macrophages, and the extent of accumulation has been correlated with the extent of LDL glycation (6, 7). In all these studies it was presumed that the glycated apoB is responsible for the entire altered activity.By using antibodies to advanced glycation end products (AGE), Bucala et al. (8) have, however, shown that the lipid component of glycated LDL contains most of the AGE present and that the relative amount of this AGE antigen was proport...